Literature DB >> 28992041

Peripheral tissue levels and molecular species compositions of N-acyl-phosphatidylethanolamine and its metabolites in mice lacking N-acyl-phosphatidylethanolamine-specific phospholipase D.

Manami Inoue1, Kazuhito Tsuboi2, Yoko Okamoto1, Mayumi Hidaka3, Toru Uyama2, Toshihiko Tsutsumi4, Tamotsu Tanaka1, Natsuo Ueda2, Akira Tokumura1,3.   

Abstract

N-acylethanolamines (NAEs), a class of lipid mediators, are produced from N-acyl-phosphatidylethanolamine (NAPE) by several pathways, including the direct release by NAPE-specific phospholipase D (NAPE-PLD) or the multistep pathway via sn-glycero-3-phospho-N-acylethanolamine (Gp-NAE). Using liquid chromatography-tandem mass spectrometry, we compared peripheral tissue levels of NAPE, Gp-NAE and NAE in NAPE-PLD-deficient (NAPE-PLD-/-) and wild type (WT) mice. NAPE-PLD was suggested to play a major role in the NAPE degradation in heart, kidney, and liver, but not in jejunum, because the NAPE levels except jejunum were significantly higher in NAPE-PLD-/- mice than in WT mice. The deletion of NAPE-PLD failed to alter the NAE levels of these tissues, suggesting its limited role in the NAE production. The enzyme assays with tissue homogenates confirmed the presence of NAPE-PLD-independent pathways in these peripheral tissues. Gp-NAE species having an acyl moiety with 22 carbons and 6 double bonds was enriched in these peripheral tissues. As for sn-2 acyl species of NAPE, 18:2-acyl-containing NAPE species were predominant over 18:1-containing species in heart, liver, and jejunum. Our results show that both molecular species composition of NAPE, NAE and Gp-NAE and their dependencies on Napepld are different among the peripheral tissues, suggesting that each tissue has distinct metabolic pathways and these NAE-containing lipids play tissue-specific roles.
© The Authors 2017. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved.

Entities:  

Keywords:  N-acyl-phosphatidylethanolamine; gene deletion; glycerophospho-N-acylethanolamine; phospholipase D; tandem mass spectrometry

Mesh:

Substances:

Year:  2017        PMID: 28992041     DOI: 10.1093/jb/mvx054

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  11 in total

1.  Symmetrically substituted dichlorophenes inhibit N-acyl-phosphatidylethanolamine phospholipase D.

Authors:  Geetika Aggarwal; Jonah E Zarrow; Zahra Mashhadi; C Robb Flynn; Paige Vinson; C David Weaver; Sean S Davies
Journal:  J Biol Chem       Date:  2020-04-13       Impact factor: 5.157

2.  Glycerophosphodiesterase 3 (GDE3) is a lysophosphatidylinositol-specific ectophospholipase C acting as an endocannabinoid signaling switch.

Authors:  Fabienne Briand-Mésange; Véronique Pons; Sophie Allart; Julien Masquelier; Gaëtan Chicanne; Nicolas Beton; Bernard Payrastre; Giulio G Muccioli; Jérôme Ausseil; Jean-Luc Davignon; Jean-Pierre Salles; Hugues Chap
Journal:  J Biol Chem       Date:  2020-09-11       Impact factor: 5.157

Review 3.  Non-endocannabinoid N-acylethanolamines and 2-monoacylglycerols in the intestine.

Authors:  Harald S Hansen; Vasiliki Vana
Journal:  Br J Pharmacol       Date:  2018-04-02       Impact factor: 8.739

4.  Impact of Circulating N-Acylethanolamine Levels with Clinical and Laboratory End Points in Hemodialysis Patients.

Authors:  Alex Y Pai; Cachet Wenziger; Elani Streja; Donovan A Argueta; Nicholas V DiPatrizio; Connie M Rhee; Nosratola D Vaziri; Kamyar Kalantar-Zadeh; Daniele Piomelli; Hamid Moradi
Journal:  Am J Nephrol       Date:  2021-02-18       Impact factor: 3.754

5.  Intestinal epithelial N-acylphosphatidylethanolamine phospholipase D links dietary fat to metabolic adaptations in obesity and steatosis.

Authors:  Amandine Everard; Hubert Plovier; Marialetizia Rastelli; Matthias Van Hul; Alice de Wouters d'Oplinter; Lucie Geurts; Céline Druart; Sylvie Robine; Nathalie M Delzenne; Giulio G Muccioli; Willem M de Vos; Serge Luquet; Nicolas Flamand; Vincenzo Di Marzo; Patrice D Cani
Journal:  Nat Commun       Date:  2019-01-28       Impact factor: 14.919

6.  Hepatic NAPE-PLD Is a Key Regulator of Liver Lipid Metabolism.

Authors:  Charlotte Lefort; Martin Roumain; Matthias Van Hul; Marialetizia Rastelli; Rita Manco; Isabelle Leclercq; Nathalie M Delzenne; Vincenzo Di Marzo; Nicolas Flamand; Serge Luquet; Cristoforo Silvestri; Giulio G Muccioli; Patrice D Cani
Journal:  Cells       Date:  2020-05-18       Impact factor: 6.600

7.  Lipidomic Analysis of Plasma from Healthy Men and Women Shows Phospholipid Class and Molecular Species Differences between Sexes.

Authors:  Annette L West; Louise V Michaelson; Elizabeth A Miles; Richard P Haslam; Karen A Lillycrop; Ramona Georgescu; Lihua Han; Johnathan A Napier; Philip C Calder; Graham C Burdge
Journal:  Lipids       Date:  2020-12-07       Impact factor: 1.880

Review 8.  Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox.

Authors:  Myriam Dao; Helene François
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-07       Impact factor: 5.555

Review 9.  Endocannabinoids and related N-acylethanolamines: biological activities and metabolism.

Authors:  Kazuhito Tsuboi; Toru Uyama; Yasuo Okamoto; Natsuo Ueda
Journal:  Inflamm Regen       Date:  2018-10-01

10.  Structural Determination of Lysosphingomyelin-509 and Discovery of Novel Class Lipids from Patients with Niemann-Pick Disease Type C.

Authors:  Masamitsu Maekawa; Isamu Jinnoh; Yotaro Matsumoto; Aya Narita; Ryuichi Mashima; Hidenori Takahashi; Anna Iwahori; Daisuke Saigusa; Kumiko Fujii; Ai Abe; Katsumi Higaki; Shosei Yamauchi; Yuji Ozeki; Kazutaka Shimoda; Yoshihisa Tomioka; Torayuki Okuyama; Yoshikatsu Eto; Kousaku Ohno; Peter T Clayton; Hiroaki Yamaguchi; Nariyasu Mano
Journal:  Int J Mol Sci       Date:  2019-10-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.